From Discovery to Decision: Building a Fit-for-Purpose Proteomics Strategy for Clinical Development
Late-stage clinical trial attrition remains one of the most expensive challenges in drug development, with more than half of Phase III programs failing to meet…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
